Oct 15, 2024 7:30 am EDT BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni
Oct 09, 2024 7:30 am EDT BullFrog AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114
Aug 26, 2024 8:00 am EDT BullFrog AI to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Jul 25, 2024 7:30 am EDT BullFrog AI and Lieber Institute for Brain Development Reveal New Insights into Bipolar Disorder Pathways and Potential Drug Targets
May 29, 2024 8:00 am EDT Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on June 12
May 16, 2024 8:00 am EDT BullFrog AI and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for Neuropsychiatric Disorders
Apr 09, 2024 8:00 am EDT BullFrog AI’s CSO, Tom Chittenden, to Present at the Quantum Computing Symposium at Bio-IT World Conference & Expo
Mar 08, 2024 8:00 am EST BullFrog AI Announces Availability of Fireside Chat Recording Featuring CEOs of BullFrog AI and the Lieber Institute
Feb 26, 2024 8:00 am EST BullFrog AI Appoints Globally Renowned Biomedical AI Expert Dr. Thomas W. Chittenden as Chief Scientific Officer
Feb 21, 2024 12:01 pm EST BullFrog AI Announces Underwriter’s Decision to Exercise Over-Allotment Option to Purchase 218,382 Shares of the Company’s Common Stock